Market Place
Sourcing Support
BioCorRx Reports Business Update for the Second Quarter of 2024
15 Aug 2024 //
GLOBENEWSWIRE
BioCorRx Awarded New Patent for Novel Compound to Treat Pain, Depression
03 Apr 2024 //
GLOBENEWSWIRE
BioCorRx Reports Business Update for 2023
02 Apr 2024 //
GLOBENEWSWIRE
BioCorRx Awarded NIDA Grant of $11M Over Three Years for Research on BICX104
28 Feb 2024 //
GLOBENEWSWIRE
BioCorRx Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
08 Feb 2024 //
GLOBENEWSWIRE
BioCorRx Appoints Louis Lucido as President
09 Jan 2024 //
GLOBENEWSWIRE
BioCorRx Reports Business Update for the Third Quarter of 2023
14 Nov 2023 //
GLOBENEWSWIRE
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104
15 Aug 2023 //
GLOBENEWSWIRE
BioCorRx Reports Business Update for the Second Quarter of 2023
14 Aug 2023 //
GLOBENEWSWIRE
BioCorRx Submits Fast Track Application to FDA for BICX104
18 Jul 2023 //
GLOBENEWSWIRE
BioCorRx Provides Business Update for the First Quarter of 2023
16 May 2023 //
GLOBENEWSWIRE
BioCorRx Provides Business Update for 2022
03 Apr 2023 //
GLOBENEWSWIRE
BioCorRx Announced Safety and Pharmacokinetic Results of Phase 1 Trial
07 Mar 2023 //
GLOBENEWSWIRE
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting
23 Feb 2023 //
GLOBENEWSWIRE
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
27 Jan 2023 //
GLOBENEWSWIRE
BioCorRx Appoints Harsha Murthy to the Board of Directors
24 Jan 2023 //
GLOBENEWSWIRE
BioCorRx Announces Preliminary Safety Data from PI Clinical Trial of BICX104
19 Jan 2023 //
GLOBENEWSWIRE
BioCorRx Partners with GovT Plus to Expand its Beat Addiction Recovery Program
07 Dec 2022 //
GLOBENEWSWIRE
BioCorRx Provides Business Update for the Third Quarter of 2022
15 Nov 2022 //
GLOBENEWSWIRE
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104
13 Oct 2022 //
GLOBENEWSWIRE
BioCorRx Provides Business Update for the Second Quarter of 2022
16 Aug 2022 //
GLOBENEWSWIRE
BioCorRx to Participate in the Benzinga All Access Event on July 15th
13 Jul 2022 //
GLOBENEWSWIRE
BioCorRx Begins Dosing in PI Trial of BICX104 for Opioid Use Disorder
30 Jun 2022 //
GLOBENEWSWIRE
BioCorRx Featured on LiveNOW from FOX
17 Jun 2022 //
GLOBENEWSWIRE
BioCorRx to Present at the LD Micro Invitational XII on June 7th
31 May 2022 //
GLOBENEWSWIRE
BioCorRx Business Update for the First Quarter of 2022
17 May 2022 //
GLOBENEWSWIRE
BioCorRx Begins Recruitment for Trial of BICX104 for Opioid Use Disorder
27 Apr 2022 //
GLOBENEWSWIRE
BioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4th
26 Apr 2022 //
ACCESSWIRE
BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104
11 Apr 2022 //
GLOBENEWSWIRE
BioCorRx Provides 2021 Year-End Business Update
01 Apr 2022 //
GLOBENEWSWIRE
BioCorRx to Participate in Two Upcoming Conferences
22 Mar 2022 //
GLOBENEWSWIRE
BioCorRx Bags IRB Approval to Begin PI Trial of BICX104 for Opioid Use Disorder
16 Mar 2022 //
GLOBENEWSWIRE
BioCorRx Announces Orange County Research Center as Trial Site of BICX104
14 Feb 2022 //
GLOBENEWSWIRE
BioCorRx Files Patent Application with USPTO for Naltrexone Implant
22 Sep 2021 //
GLOBENEWSWIRE
Recro acquires opioid addiction drug maker, will handle all FDA formalities
09 Sep 2021 //
ENDPTS
BioCorRx awards $3.5M NIDA Grant for Trial of BICX104 in Opioid Use Disorder
01 Sep 2021 //
GLOBENEWSWIRE
BioCorRx Provides Business Update for the Second Quarter of 2021
16 Aug 2021 //
GLOBENEWSWIRE
BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board
22 Jun 2021 //
GLOBENEWSWIRE
BioCorRx Receives FDA Clearance of Investigational New Drug (IND) for BICX104
10 May 2021 //
GLOBENEWSWIRE
BioCorRx Announces Submission of IND Application to the FDA for BICX104
13 Apr 2021 //
GLOBENEWSWIRE
BioCorRx Provides Update on Current Business Operations GLP Studies of BICX102
22 May 2020 //
GLOBENEWSWIRE
